Abstract
A key barrier to the development of gene therapy remains the lack of safe, efficient and easily controllable vehicles for gene delivery. The fundamental problems associated with the viral vehicles, e.g. lack of specificity and immunogenic potential, have driven the development of non-viral systems of gene delivery. In the last decade, studies on p53 gene replacement therapy have dominated the literature. Although clinical trials of p53 gene therapy have achieved limited success, it remains the only tumor suppressor gene to be evaluated formally in clinical trials for cancer treatment, with increasing focus on delivery using non-viral systems. In this article, we particularly review current investigations on p53 gene delivery using non-viral methods, including both physical and chemical approaches, with an emphasis on the latter. The existing opportunities and challenges for successful p53 cancer gene therapy are also discussed.
Keywords: p53, gene therapy, non-viral vectors, cancer, combination therapy.
Current Medicinal Chemistry
Title:Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Volume: 22 Issue: 35
Author(s): Kai Wang, Qian Huang, Fuming Qiu and Meihua Sui
Affiliation:
Keywords: p53, gene therapy, non-viral vectors, cancer, combination therapy.
Abstract: A key barrier to the development of gene therapy remains the lack of safe, efficient and easily controllable vehicles for gene delivery. The fundamental problems associated with the viral vehicles, e.g. lack of specificity and immunogenic potential, have driven the development of non-viral systems of gene delivery. In the last decade, studies on p53 gene replacement therapy have dominated the literature. Although clinical trials of p53 gene therapy have achieved limited success, it remains the only tumor suppressor gene to be evaluated formally in clinical trials for cancer treatment, with increasing focus on delivery using non-viral systems. In this article, we particularly review current investigations on p53 gene delivery using non-viral methods, including both physical and chemical approaches, with an emphasis on the latter. The existing opportunities and challenges for successful p53 cancer gene therapy are also discussed.
Export Options
About this article
Cite this article as:
Wang Kai, Huang Qian, Qiu Fuming and Sui Meihua, Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy, Current Medicinal Chemistry 2015; 22 (35) . https://dx.doi.org/10.2174/0929867322666151001121601
DOI https://dx.doi.org/10.2174/0929867322666151001121601 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Delivery Systems of Green Tea Catechins for Improved Stability and Bioavailability
Current Medicinal Chemistry Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design Inhibition of PCAF by Anacardic Acid Derivative Leads to Apoptosis and Breaks Resistance to DNA Damage in BCR-ABL-expressing Cells
Anti-Cancer Agents in Medicinal Chemistry Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy
Current Genomics Antibacterial Vaccine Research in 21st Century: From Inoculation to Genomics Approaches
Current Topics in Medicinal Chemistry The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.
Current Medicinal Chemistry Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry The Effect of Drugs on the Labeling of Blood Elements with Technetium-99m
Current Pharmaceutical Design Metabolic Cooperation in Testis as a Pharmacological Target: From Disease to Contraception
Current Molecular Pharmacology EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Dietary Manipulation of Precursor Polyunsaturated Fatty Acids Modulates Eicosanoid and Endocannabinoid Synthesis: A Potential Tool to Control Tumor Development
Current Nutrition & Food Science Distinct Epigenetic Reprogramming, Mitochondrial Patterns, Cellular Morphology, and Cytotoxicity after Bee Venom Treatment
Recent Patents on Anti-Cancer Drug Discovery Metals and Metal Derivatives in Medicine
Mini-Reviews in Medicinal Chemistry Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Endometriosis and Gynecological Cancer
Current Women`s Health Reviews Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets